Risk factors and outcomes for repeat COVID-19 infection among patients with systemic autoimmune rheumatic diseases: A case-control study-Reference-Cited by-同舟云学术

Risk factors and outcomes for repeat COVID-19 infection among patients with systemic autoimmune rheumatic diseases: A case-control study

Published:2023-12 Issue: Volume:63 Page:152286
ISSN:0049-0172
Container-title:Seminars in Arthritis and Rheumatism
language:en
Short-container-title:Seminars in Arthritis and Rheumatism

Author:

Kowalski Emily N.,Wang Xiaosong,Patel Naomi J.,Kawano Yumeko,Cook Claire E.,Vanni Kathleen M.M.,Qian Grace,Bade Katarina J.,Srivatsan Shruthi,Williams Zachary K.,Wallace Zachary S.,Sparks Jeffrey A.^ORCID

Funder

National Institutes of Health

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Publisher

Elsevier BV

Subject

Anesthesiology and Pain Medicine,Rheumatology

Reference42 articles.

1. COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: a US multicenter, comparative cohort study;D'Silva;Arthritis Rheumatol,2021

2. SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: a systematic literature review and meta-analysis;Conway;Arthritis Rheumatol,2022

3. Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave;Kawano;Ann Rheum Dis,2022

4. SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity;Pilz;Environ Res,2022

5. Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions;Krasselt;Rheumatology,2022

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Do rheumatic diseases, long‐term glucocorticoids, and immunosuppressant treatment, and vaccination impact the COVID‐19 severity? Insight from a retrospective cohort study;International Journal of Rheumatic Diseases;2024-07

2. COVID‐19 Vaccination Before Initiating Rituximab Treatment Induces Strong Serological Response in Autoimmune Rheumatic Disease, Reducing Post‐Pandemic Concerns About the Impact of Rituximab;ACR Open Rheumatology;2024-06-23

3. Associations of DMARDs with post-acute sequelae of COVID-19 in patients with systemic autoimmune rheumatic diseases: a prospective study;Rheumatology;2023-12-09